Publication dates

All regions

Cancer Industry, September 2014 Market Reports from Top Publishers

You might be interested in: medical equipment, therapeutics, prostate cancer, more »


 
1-20 of about 141 000 reports for Cancer

Future Horizons and Growth Strategies in the European Tumor Marker Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the European Tumor Marker Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 12 800
  • Industry report
  • August 2014
  • by Venture Planning Group

... The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery ...

Colon Carcinoma - Pipeline Review, H2 2014

Colon Carcinoma - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

Colon Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Colon Carcinoma - Pipeline Review, H2 2014', provides an overview of the Colon Carcinoma's therapeutic pipeline. This report ...

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

  • $ 5 995
  • Industry report
  • August 2014
  • by Global Data

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 Summary The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the ...

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • August 2014
  • by Global Data

... Is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine ...

Onyx Pharmaceuticals, Inc. (Symbol:ONXX) SWOT Analysis, Strategy, Revenues and Profits

Onyx Pharmaceuticals, Inc. (Symbol:ONXX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • August 2014
  • by Global Data

... Is a biopharmaceutical company, which develops and commercializes innovative medicines that target the molecular mechanisms causing cancer. It has two oncology franchises one in kinase inhibition and other in proteasome ...

Constellation Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Constellation Pharmaceuticals, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • August 2014
  • by Global Markets Direct

... Constellation pharmaceuticals, inc. - Drug profiles 11cpi-0610 11product description 11mechanism of action 11r&d progress 11small molecules to inhibit bet for cancer 12product description 12 ...

Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies

Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies

  • $ 3 900
  • Industry report
  • August 2014
  • by Firstword Pharma

... In the areas of breast cancer, melanoma, nsclc, and renal cell carcinomaunderstand the key issues for which physicians require medical affairs team support ...

Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018

Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018

  • $ 4 650
  • Industry report
  • August 2014
  • by MarketsandMarkets

... And animal research. Diagnostics emerged as the largest whole exome sequencing application, primarily because of an increase in the usage of exome sequencing technologies in cancer and rare disease research ...

Metabolon, Inc. - Product Pipeline Analysis, 2014 Update

Metabolon, Inc. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • August 2014
  • by Global Data

... Early-stage insulin resistance; and prostarix and prostarix plus tests are urine-based tests used in the detection of prostate cancer risk. The company partners with glaxosmithkline, takeda, bostwick ...

XEPTAGEN SpA - Product Pipeline Analysis, 2014 Update

XEPTAGEN SpA - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • August 2014
  • by Global Data

... Diagnostic kits for the early detection, monitoring, and screening of cancerous cells. Its products include hepa afp-ic, colonic, hepa ab, hepa ic, prostateic and sccalisa. The company develops ...

About 24 000 reports for Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Cancer Statistics, 2013
  • January 2013
    20 pages
  • Cancer  

  • United States  

    North America  

View report >

81 Companies for Cancer

Read our Company Profiles

Novartis Inc.

Switzerland

Cepheid

United States

GlaxoSmithKline P.L.C.

United States

AstraZeneca PLC

United Kingdom

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.